Shamburg News · 8-K filed Nov 17, 2026, 7:14 AM EST
SELLAS Life Sciences Reports Positive Phase 3 REGAL Trial Results for Galinpepimut-S in AML
SLS · SELLAS Life Sciences Group, Inc.
- Other event
- Material agreement
- Materiality: high
On November 17, 2026, SELLAS Life Sciences Group, Inc. announced positive topline results from the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia. The trial met its primary overall survival endpoint, with median OS of 24.0 months for GPS-treated patients versus 14.7 months for best available treatment, a hazard ratio of 0.59 and a two-sided p=0.035. The company plans to meet with the FDA to discuss an accelerated filing strategy and advance preparations for a BLA submission in the first half of 2027.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, accession 0001104659-26-128825.
Written from the filing by Shamburg Markets. Figures are as reported by the company.